| Recent progress and considerations for AAV gene therapies targeting the central nervous system EA Lykken, C Shyng, RJ Edwards, A Rozenberg, SJ Gray Journal of neurodevelopmental disorders 10, 1-10, 2018 | 158 | 2018 |
| An anti-neuroinflammatory that targets dysregulated glia enhances the efficacy of CNS-directed gene therapy in murine infantile neuronal ceroid lipofuscinosis SL Macauley, AMS Wong, C Shyng, DP Augner, JT Dearborn, Y Pearse, ... Journal of Neuroscience 34 (39), 13077-13082, 2014 | 72 | 2014 |
| Synergistic effects of treating the spinal cord and brain in CLN1 disease C Shyng, HR Nelvagal, JT Dearborn, J Tyynelä, RE Schmidt, MS Sands, ... Proceedings of the National Academy of Sciences 114 (29), E5920-E5929, 2017 | 61 | 2017 |
| Dual-isoform hUBE3A gene transfer improves behavioral and seizure outcomes in Angelman syndrome model mice MC Judson, C Shyng, JM Simon, CR Davis, AM Punt, MT Salmon, ... JCI insight 6 (20), 2021 | 25 | 2021 |
| Astrocytosis in infantile neuronal ceroid lipofuscinosis: friend or foe? C Shyng, MS Sands Biochemical Society Transactions 42 (5), 1282-1285, 2014 | 14 | 2014 |
| Histochemical localization of palmitoyl protein thioesterase-1 activity JT Dearborn, S Ramachandran, C Shyng, JY Lu, J Thornton, SL Hofmann, ... Molecular genetics and metabolism 117 (2), 210-216, 2016 | 12 | 2016 |
| Widespread expression of a membrane-tethered version of the soluble lysosomal enzyme palmitoyl protein thioesterase-1 C Shyng, SL Macauley, JT Dearborn, MS Sands JIMD Reports, Volume 36, 85-92, 2017 | 8 | 2017 |
| SMRT Sequencing Enables High-Throughput Identification of Novel AAVs from Capsid Shuffling and Directed Evolution W Casy, IT Garza, X Chen, T Dong, Y Hu, M Kanchwala, CB Trygg, ... Genes 14 (8), 1660, 2023 | 1 | 2023 |
| Influence of background enzyme replacement therapy on baseline biomarker profiles of patients with Fabry disease U Cagin, A Culbert, R Meng, R Wang, C Coachys, E Cudo, R Paul, ... Molecular Genetics and Metabolism 141 (2), 107784, 2024 | | 2024 |
| Ube3a genes and expression cassettes and their use BD Philpot, SJ Gray, C Shyng, M Judson | | 2023 |
| Investigational liver gene transfer of alpha galactosidase for the treatment of Fabry disease C Shyng, U Chagin, C Coachys, S Ioele, A Nowrouzi, A Rohacek, S Elliott, ... Molecular Genetics and Metabolism 138 (2), 107319, 2023 | | 2023 |
| Ube3a genes and expression cassettes and their use BD Philpot, SJ Gray, C Shyng, M Judson US Patent App. 17/612,833, 2022 | | 2022 |
| Investigational Liver Gene Transfer of Alpha Galactosidase for the Treatment of Fabry Disease C Shyng, A Nowrouzi, S Ioele, U Cagin, S Ashley, S Elliot, A Rohacek, ... MOLECULAR THERAPY 30 (4), 115-115, 2022 | | 2022 |
| Characterization of New Pfizer AAV Vectors C Shyng, M Michalec, K Zaraspe, T Cheng, R Tabet, LJ Song, JC Pang, ... MOLECULAR THERAPY 29 (4), 174-175, 2021 | | 2021 |
| Ube3a genes and expression cassettes and their use BD Philpot, SJ GREY, C SHYNG, M JUDSON | | 2020 |
| Early gait abnormalities relate to brainstem and spinal cord pathology in CLN1 disease HR Nelvagal, C Shyng, MS Sands, JD Cooper Molecular Genetics and Metabolism 123 (2), S104, 2018 | | 2018 |
| 27. Therapeutic Efficacy of Intracranial and Intrathecal AAV2/9-PPT1 in Infantile Batten Disease C Shyng, HR Nelvagal, JT Dearborn, JD Cooper, MS Sands Molecular Therapy 24, S12-S13, 2016 | | 2016 |
| Infantile Batten Disease: Effective Therapy and Novel Model C Shyng Washington University in St. Louis, 2016 | | 2016 |
